Infinity PhII results a blow for PI3K in inflammation
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals has discontinued development of its oral PI3K inhibitor duvelisib in rheumatoid arthritis after the candidate failed in a Phase II trial.
You may also be interested in...
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Need a specific report? 1000+ reports available
Buy Reports